{"transactions":[{"id":824646,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":55175,"kind":"person","name":"QUAY STEVEN C","position":1,"cik":"0001008227","reported_name":"QUAY STEVEN C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-03-31T16:57:01.000Z","date":"2026-03-27","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal annual installments on the first three anniversaries of March 26, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On February 2, 2026, the Issuer effected a one-for-fifteen reverse stock split of its Common Stock (the \"Reverse Stock Split\"). The number of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split."}],"balance_after":88038,"source":{"system":"sec-edgar","filing":"0001193125-26-134861","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008227/000119312526134861/ownership.xml","form_type":"4"}},{"id":927405,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":55175,"kind":"person","name":"QUAY STEVEN C","position":1,"cik":"0001008227","reported_name":"QUAY STEVEN C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Options (right to buy)","published_at":"2026-01-30T08:30:03.000Z","date":"2026-01-20","kind":"grant","planned":false,"acquired":true,"shares":950000,"price":0.603,"value":572850.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options shall vest on a quarterly basis over 24 months following January 20, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. The options were issued on January 20, 2026, with an exercise price of $0.603, representing the closing stock price on January 20, 2026."}],"balance_after":950000,"derivative":{"exercise_price":0.603,"expiration_date":"2026-01-20","underlying":"Common Stock","underlying_shares":950000},"source":{"system":"sec-edgar","filing":"0001193125-26-030571","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1008227/000119312526030571/ownership.xml","form_type":"4/A","original_submission_date":"2026-01-22"}},{"id":927404,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":55175,"kind":"person","name":"QUAY STEVEN C","position":1,"cik":"0001008227","reported_name":"QUAY STEVEN C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-30T08:30:03.000Z","date":"2026-01-20","kind":"grant","planned":false,"acquired":true,"shares":331674,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the acquisition of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest one year from the Transaction Date."},{"field":"shares","element":"transactionShares","label":"F2","text":"The original Form 4, filed on January 22, 2026, is being amended by this Form 4 amendment solely to correct an administrative error regarding the number of RSUs acquired."}],"balance_after":345572,"source":{"system":"sec-edgar","filing":"0001193125-26-030571","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008227/000119312526030571/ownership.xml","form_type":"4/A","original_submission_date":"2026-01-22"}},{"id":933670,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":55175,"kind":"person","name":"QUAY STEVEN C","position":1,"cik":"0001008227","reported_name":"QUAY STEVEN C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Options (right to buy)","published_at":"2026-01-22T14:11:52.000Z","date":"2026-01-20","kind":"grant","planned":false,"acquired":true,"shares":950000,"price":0.603,"value":572850.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options shall vest on a quarterly basis over 24 months following January 20, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. The options were issued on January 20, 2026, with an exercise price of $0.603, representing the closing stock price on January 20, 2026."}],"balance_after":950000,"derivative":{"exercise_price":0.603,"expiration_date":"2026-01-20","underlying":"Common Stock","underlying_shares":950000},"source":{"system":"sec-edgar","filing":"0001193125-26-019273","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1008227/000119312526019273/ownership.xml","form_type":"4"}},{"id":933669,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":55175,"kind":"person","name":"QUAY STEVEN C","position":1,"cik":"0001008227","reported_name":"QUAY STEVEN C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-22T14:11:52.000Z","date":"2026-01-20","kind":"grant","planned":false,"acquired":true,"shares":325203,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the acquisition of restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest one year from the Transaction date."}],"balance_after":339101,"source":{"system":"sec-edgar","filing":"0001193125-26-019273","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008227/000119312526019273/ownership.xml","form_type":"4"}},{"id":1138042,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":55175,"kind":"person","name":"QUAY STEVEN C","position":1,"cik":"0001008227","reported_name":"QUAY STEVEN C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2025-05-22T18:27:25.000Z","date":"2025-05-21","kind":"purchase","planned":false,"acquired":true,"shares":11239,"price":0.8797,"value":9886.9483,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average purchase price per share. The shares were purchased in multiple transactions at prices ranging from $0.8794 to $0.9100. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of share purchased at each separate price."}],"balance_after":13898,"source":{"system":"sec-edgar","filing":"0000950170-25-076523","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008227/000095017025076523/ownership.xml","form_type":"4"}},{"id":1146104,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":55175,"kind":"person","name":"QUAY STEVEN C","position":1,"cik":"0001008227","reported_name":"QUAY STEVEN C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-05-16T16:05:17.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":1366062,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest on a quarterly basis over 24 months following May 15, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. The options were issued on May 15, 2025, with an exercise price of $0.99, representing the closing stock price on May 15, 2025."}],"balance_after":1366062,"derivative":{"exercise_price":0.99,"expiration_date":"2035-05-15","underlying":"Common Stock","underlying_shares":1366062},"source":{"system":"sec-edgar","filing":"0000950170-25-073520","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008227/000095017025073520/ownership.xml","form_type":"4"}},{"id":1466479,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":55175,"kind":"person","name":"QUAY STEVEN C","position":1,"cik":"0001008227","reported_name":"QUAY STEVEN C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-07-01T16:00:07.000Z","date":"2024-06-27","kind":"grant","planned":false,"acquired":true,"shares":1795100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest on a quarterly basis over 24 months following June 27, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. The options were issued at approximately 9:30 a.m. (ET) on June 27, 2024, with an exercise price of $1.05, representing the most recently reported closing stock price on June 26, 2024."}],"balance_after":1795100,"derivative":{"exercise_price":1.05,"expiration_date":"2034-06-27","underlying":"Common Stock","underlying_shares":1795100},"source":{"system":"sec-edgar","filing":"0000950170-24-079559","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008227/000095017024079559/ownership.xml","form_type":"4"}},{"id":1970007,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":55175,"kind":"person","name":"QUAY STEVEN C","position":1,"cik":"0001008227","reported_name":"QUAY STEVEN C","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Stock Option  (right to buy)","published_at":"2023-03-06T16:11:04.000Z","date":"2023-03-02","kind":"grant","acquired":true,"shares":1873100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest and become exercisable on a quarterly basis over 24 months from the grant-date."}],"balance_after":1873100,"derivative":{"exercise_price":0.72,"expiration_date":"2033-03-02","underlying":"Common Stock","underlying_shares":1873100},"source":{"system":"sec-edgar","filing":"0001437749-23-005533","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008227/000143774923005533/rdgdoc.xml","form_type":"4"}},{"id":2369932,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":55175,"kind":"person","name":"QUAY STEVEN C","position":1,"cik":"0001008227","reported_name":"QUAY STEVEN C","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-28T17:15:56.000Z","date":"2022-02-24","kind":"grant","acquired":true,"shares":1900000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest on a quarterly basis over two (2) years."}],"balance_after":1900000,"derivative":{"exercise_price":1.25,"expiration_date":"2032-02-24","underlying":"Common Stock","underlying_shares":1900000},"source":{"system":"sec-edgar","filing":"0001437749-22-004667","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008227/000143774922004667/rdgdoc.xml","form_type":"4"}},{"id":2708857,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":55175,"kind":"person","name":"QUAY STEVEN C","position":1,"cik":"0001008227","reported_name":"QUAY STEVEN C","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-05-18T16:18:50.000Z","date":"2021-05-14","kind":"grant","acquired":true,"shares":1900000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest on a quarterly basis over the next 24 months. Option grant was issued at 4:30 p.m. (ET) on May 14, 2021 with an exercise price of $2.90, representing the most recently reported closing stock price at the time of grant."}],"balance_after":1900000,"derivative":{"exercise_price":2.9,"expiration_date":"2031-05-14","underlying":"Common Stock","underlying_shares":1900000},"source":{"system":"sec-edgar","filing":"0001437749-21-012676","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008227/000143774921012676/rdgdoc.xml","form_type":"4"}},{"id":2708858,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":55175,"kind":"person","name":"QUAY STEVEN C","position":1,"cik":"0001008227","reported_name":"QUAY STEVEN C","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2021-05-18T16:18:22.000Z","date":"2021-05-14","kind":"grant","acquired":true,"shares":1900000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest on a quarterly basis over the next 24 months. Option grant was issued at 4:30 p.m. (ET) on May 14, 2021 with an exercise price of $2.90, representing the most recently reported closing stock price at the time of grant."}],"balance_after":1900000,"derivative":{"exercise_price":2.9,"expiration_date":"2031-05-14","underlying":"Common Stock","underlying_shares":1900000},"source":{"system":"sec-edgar","filing":"0001437749-21-012674","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008227/000143774921012674/rdgdoc.xml","form_type":"4"}},{"id":3178189,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":55175,"kind":"person","name":"QUAY STEVEN C","position":1,"cik":"0001008227","reported_name":"QUAY STEVEN C","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-13T18:20:39.000Z","date":"2020-04-09","kind":"grant","acquired":true,"shares":1305000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest quarterly in equal amounts over two years from the grant date (April 9, 2020), subject to continued employment with the Company through the applicable vesting dates.  However, 50% of all then-unvested options will vest immediately upon the achievement of certain milestones. The stock options are also subject to stockholder approval of the 2020 Stock Incentive Plan of the Company, which approval must occur within one year from the grant date."}],"balance_after":1305000,"derivative":{"exercise_price":1.48,"expiration_date":"2030-04-09","underlying":"Common Shares","underlying_shares":1305000},"source":{"system":"sec-edgar","filing":"0001437749-20-007628","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1008227/000143774920007628/rdgdoc.xml","form_type":"4"}},{"id":3178188,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":55175,"kind":"person","name":"QUAY STEVEN C","position":1,"cik":"0001008227","reported_name":"QUAY STEVEN C","relationship":{"director":true,"officer":true,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-13T18:20:39.000Z","date":"2020-04-09","kind":"grant","acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest quarterly in equal amounts over two years from the grant date (April 9, 2020), subject to continued employment with the Company through the applicable vesting dates."}],"balance_after":195000,"derivative":{"exercise_price":1.48,"expiration_date":"2030-04-09","underlying":"Common Shares","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0001437749-20-007628","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008227/000143774920007628/rdgdoc.xml","form_type":"4"}},{"id":3695791,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":55175,"kind":"person","name":"QUAY STEVEN C","position":1,"cik":"0001008227","reported_name":"QUAY STEVEN C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-15T16:10:46.000Z","date":"2019-01-13","kind":"grant","acquired":true,"shares":2300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The June 27, 2018 options are being rescinded and a new option is being granted in order to: (i) impose a shareholder-approval requirement for the new option grant, and (ii) remove the cash settlement feature and associated liability from the June 27, 2018 grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to stockholder approval of the option grant, the option will vest and be exercisable with respect to: (i) 25% of the underlying shares as of the grant date (January 13, 2019), (ii) 50% of the underlying shares over a two-year period (vesting ratably quarterly) from June 27, 2018, and (iii) 25% of the underlying shares upon achievement of certain milestones. If the option grant is not approved by stockholders, then the option will not be exercisable."}],"balance_after":2300000,"derivative":{"exercise_price":1.36,"expiration_date":"2029-01-13","underlying":"Common Shares","underlying_shares":2300000},"source":{"system":"sec-edgar","filing":"0001615774-19-000645","document":"s115379_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1008227/000161577419000645/s115379_form4.xml","form_type":"4"}},{"id":3695790,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":55175,"kind":"person","name":"QUAY STEVEN C","position":1,"cik":"0001008227","reported_name":"QUAY STEVEN C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-15T16:10:46.000Z","date":"2019-01-13","kind":"disposition_to_issuer","acquired":false,"shares":2300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The June 27, 2018 options are being rescinded and a new option is being granted in order to: (i) impose a shareholder-approval requirement for the new option grant, and (ii) remove the cash settlement feature and associated liability from the June 27, 2018 grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent of the options were vested as of the grant date (June 27, 2018), 50% of the options will vest quarterly over two years from the grant date, and the remaining 25% will vest upon achievement of certain milestones."}],"balance_after":0,"derivative":{"exercise_price":2.38,"expiration_date":"2028-06-27","underlying":"Common Shares","underlying_shares":2300000},"source":{"system":"sec-edgar","filing":"0001615774-19-000645","document":"s115379_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008227/000161577419000645/s115379_form4.xml","form_type":"4"}},{"id":3880781,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":55175,"kind":"person","name":"QUAY STEVEN C","position":1,"cik":"0001008227","reported_name":"QUAY STEVEN C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2018-06-29T16:03:14.000Z","date":"2018-06-27","kind":"grant","acquired":true,"shares":2300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent of the options have vested as of the grant date, 50% of the options will vest quarterly over two years, and the remaining 25% will vest upon achievement of certain milestones."}],"balance_after":2300000,"derivative":{"exercise_price":2.38,"expiration_date":"2028-06-27","underlying":"Common Stock","underlying_shares":2300000},"source":{"system":"sec-edgar","filing":"0001615774-18-005997","document":"s111131_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008227/000161577418005997/s111131_form4.xml","form_type":"4"}},{"id":3913075,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":55175,"kind":"person","name":"QUAY STEVEN C","position":1,"cik":"0001008227","reported_name":"QUAY STEVEN C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Warrants","published_at":"2018-05-31T15:26:44.000Z","date":"2018-05-30","kind":"purchase","acquired":true,"shares":2272,"price":1000,"value":2272000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Shares of Series B Convertible Preferred Stock and Warrants were issued as part of a unit, with each unit consisting of one share of Series B Convertible Preferred Stock and 284 Warrants."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Securities are owned by Ensisheim Partners, LLC (\"Ensisheim\"). Shu-Chih Chen, Ph.D. and Steven C. Quay, M.D., Ph.D., share voting and investment power over the securities held by Ensisheim. Ensisheim is solely owned and controlled by Drs. Chen and Quay, and, as a result, Drs. Chen and Quay are deemed to be beneficial owners of the shares held by this entity."}],"balance_after":2272,"derivative":{"exercise_price":4.05,"exercise_date":"2018-05-30","expiration_date":"2022-05-30","underlying":"Common Stock","underlying_shares":2272},"source":{"system":"sec-edgar","filing":"0001615774-18-004657","document":"s110546_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1008227/000161577418004657/s110546_form4.xml","form_type":"4"}},{"id":3913074,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":55175,"kind":"person","name":"QUAY STEVEN C","position":1,"cik":"0001008227","reported_name":"QUAY STEVEN C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-05-31T15:26:44.000Z","date":"2018-05-30","kind":"purchase","acquired":true,"shares":8,"price":1000,"value":8000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Convertible Preferred Stock is convertible into the number of shares of Common Stock equal to the stated value of $1,000 divided by $3.52."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Shares of Series B Convertible Preferred Stock and Warrants were issued as part of a unit, with each unit consisting of one share of Series B Convertible Preferred Stock and 284 Warrants."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares of Series B Convertible Preferred Stock do not expire."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"No fractional shares will be issued upon conversion. At its election, the Company will either issue a cash adjustment or round up to the next whole share. The number reflected here assumes rounding up to the next whole share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Securities are owned by Ensisheim Partners, LLC (\"Ensisheim\"). Shu-Chih Chen, Ph.D. and Steven C. Quay, M.D., Ph.D., share voting and investment power over the securities held by Ensisheim. Ensisheim is solely owned and controlled by Drs. Chen and Quay, and, as a result, Drs. Chen and Quay are deemed to be beneficial owners of the shares held by this entity."}],"balance_after":8,"derivative":{"exercise_price":3.52,"exercise_date":"2018-05-30","underlying":"Common Stock","underlying_shares":2273},"source":{"system":"sec-edgar","filing":"0001615774-18-004657","document":"s110546_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008227/000161577418004657/s110546_form4.xml","form_type":"4"}},{"id":4303619,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":55175,"kind":"person","name":"QUAY STEVEN C","position":1,"cik":"0001008227","reported_name":"QUAY STEVEN C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2017-05-26T13:48:05.000Z","date":"2017-05-24","kind":"grant","acquired":true,"shares":575893,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest on a quarterly basis over the next 48 months."}],"balance_after":651785,"derivative":{"exercise_price":0.47,"expiration_date":"2027-05-24","underlying":"Common Stock","underlying_shares":575893},"source":{"system":"sec-edgar","filing":"0001615774-17-002743","document":"s106363_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1008227/000161577417002743/s106363_form4.xml","form_type":"4"}}]}